Clinical management of adrenocortical carcinoma

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 23, Issue 2, 2009, Pages 273-289

  Fassnacht, Martin ^a   Allolio, Bruno ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

adrenal cancer; diagnosis; mitotane; prognosis; radiotherapy; staging; treatment

Indexed keywords

AMINOGLUTETHIMIDE; BEVACIZUMAB; CAPECITABINE; CISPLATIN; DOXORUBICIN; ERLOTINIB; ETOMIDATE; ETOPOSIDE; GEFITINIB; GEMCITABINE; HYDROCORTISONE; KETOCONAZOLE; METYRAPONE; MIFEPRISTONE; MITOTANE; PACLITAXEL; SORAFENIB; STREPTOZOCIN; SUNITINIB; THALIDOMIDE;

ADDISON DISEASE; ADRENAL CORTEX CARCINOMA; ADRENAL INSUFFICIENCY; ADRENALECTOMY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMINURIA; ANEMIA; ANOREXIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATAXIA; AUTOIMMUNE HEPATITIS; BILIRUBIN BLOOD LEVEL; BLEEDING TIME; BLURRED VISION; CANCER STAGING; CARDIOVASCULAR DISEASE; CATARACT; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONFUSION; CONTINUOUS INFUSION; CUSHING SYNDROME; DEPRESSION; DIARRHEA; DIPLOPIA; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG TOLERABILITY; ENDOCRINE FUNCTION TEST; FATIGUE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; GYNECOMASTIA; HEMATURIA; HEMORRHAGIC CYSTITIS; HISTOPATHOLOGY; HORMONE SUBSTITUTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOGONADISM; HYPOTHYROIDISM; LAPAROSCOPIC SURGERY; LETHARGY; LEUKOPENIA; LIOTHYRONINE BLOOD LEVEL; LIVER METASTASIS; MEMORY DISORDER; MUCOSA INFLAMMATION; NAUSEA; OVERALL SURVIVAL; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PROGNOSIS; RETINA MACULA EDEMA; RETINOPATHY; REVIEW; SALVAGE THERAPY; SIDE EFFECT; SOMNOLENCE; TESTOSTERONE BLOOD LEVEL; THROMBOCYTOPENIA; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; TUMOR RECURRENCE; VERTIGO; VOMITING;

ADRENAL CORTEX HORMONES; ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; ANIMALS; DISEASE PROGRESSION; HUMANS; NEOPLASM STAGING; PROGNOSIS;

EID: 66149163113     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beem.2008.10.008     Document Type: Review

References (100)

1. Grumbach M.M., Biller B.M., Braunstein G.D., et al. Management of the clinically inapparent adrenal mass ('incidentaloma'). Annals of Internal Medicine 138 (2003) 424-429
2. Mansmann G., Lau J., Balk E., et al. The clinically inapparent adrenal mass: update in diagnosis and management. Endocrine Reviews 25 (2004) 309-340
3. Bovio S., Cataldi A., Reimondo G., et al. Prevalence of adrenal incidentaloma in a contemporary computerized tomography series. Journal of Endocrinological Investigation 29 (2006) 298-302
4. Song J.H., Chaudhry F.S., and Mayo-Smith W.W. The incidental adrenal mass on CT: prevalence of adrenal disease in 1,049 consecutive adrenal masses in patients with no known malignancy. AJR American Journal of Roentgenology 190 (2008) 1163-1168
5. National-Cancer-Institute Third National Cancer Survey: Incidenca Data. DHEW Publ. No. (NIH) 75-787. NCI monograph (1975) 41
6. Wajchenberg B., Albergaria P.M., Medonca B., et al. Adrenocortical carcinoma: clinical and laboratory observations. Cancer 88 (2000) 711-736
7. Dackiw A.P., Lee J.E., Gagel R.F., et al. Adrenal cortical carcinoma. World Journal of Surgery 25 (2001) 914-926
8. Allolio B., and Fassnacht M. Clinical review: adrenocortical carcinoma: clinical update. The Journal of Clinical Endocrinology and Metabolism 91 (2006) 2027-2037
9. Kebebew E., Reiff E., Duh Q.Y., et al. Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress?. World Journal of Surgery 30 (2006) 872-878
10. Luton J.P., Cerdas S., Billaud L., et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. The New England Journal of Medicine 322 (1990) 1195-1201
11. Wooten M.D., and King D.K. Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature. Cancer 72 (1993) 3145-3155
12. Icard P., Goudet P., Charpenay C., et al. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World Journal of Surgery 25 (2001) 891-897
13. Koschker A.K., Fassnacht M., Hahner S., et al. Adrenocortical carcinoma: improving patient care by establishing new structures. Experimental and Clinical Endocrinology & Diabetes 114 (2006) 45-51
14. Abiven G., Coste J., Groussin L., et al. Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. The Journal of Clinical Endocrinology and Metabolism 91 (2006) 2650-2655
15. Libe R., Fratticci A., and Bertherat J. Adrenocortical cancer: pathophysiology and clinical management. Endocr Relat Cancer 14 (2007) 13-28
16. Seccia T.M., Fassina A., Nussdorfer G.G., et al. Aldosterone-producing adrenocortical carcinoma: an unusual cause of Conn's syndrome with an ominous clinical course. Endocr Relat Cancer 12 (2005) 149-159
17. Arlt W, Hahner S, Libe R, et al. Steroid profiling in the diagnosis and monitoring of adrenocortical cancer - results of the EURINE ACC Study of the European Network For The Study Of Adrenal Tumors (ENS@T). Abstracts of the 90th annual meeting of the Endocrine Society, San Francisco; 2008. p. OR40-2.
18. Barzon L., and Boscaro M. Diagnosis and management of adrenal incidentalomas. The Journal of Urology 163 (2000) 398-407
19. Mantero F., Terzolo M., Arnaldi G., et al. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. The Journal of Clinical Endocrinology and Metabolism 85 (2000) 637-644
20. Fassnacht M., Kenn W., and Allolio B. Adrenal tumors: how to establish malignancy?. Journal of Endocrinological Investigation 27 (2004) 387-399
21. Ilias I., Sahdev A., Reznek R.H., et al. The optimal imaging of adrenal tumours: a comparison of different methods. Endocr Relat Cancer 14 (2007) 587-599
22. Heinz-Peer G., Memarsadeghi M., and Niederle B. Imaging of adrenal masses. Current Opinion in Urology 17 (2007) 32-38
23. Boland G.W., Lee M.J., Gazelle G.S., et al. Characterization of adrenal masses using unenhanced CT: an analysis of the CT literature. AJR American Journal of Roentgenology 171 (1998) 201-204
24. Hamrahian A.H., Ioachimescu A.G., Remer E.M., et al. Clinical utility of noncontrast computed tomography attenuation value (hounsfield units) to differentiate adrenal adenomas/hyperplasias from nonadenomas: Cleveland Clinic experience. The Journal of Clinical Endocrinology and Metabolism 90 (2005) 871-877
25. Pena C.S., Boland G.W., Hahn P.F., et al. Characterization of indeterminate (lipid-poor) adrenal masses: use of washout characteristics at contrast-enhanced CT. Radiology 217 (2000) 798-802
26. Caoili E.M., Korobkin M., Francis I.R., et al. Adrenal masses: characterization with combined unenhanced and delayed enhanced CT. Radiology 222 (2002) 629-633
27. Szolar D.H., Korobkin M., Reittner P., et al. Adrenocortical carcinomas and adrenal pheochromocytomas: mass and enhancement loss evaluation at delayed contrast-enhanced CT. Radiology 234 (2005) 479-485
28. Park B.K., Kim C.K., Kim B., et al. Comparison of delayed enhanced CT and chemical shift MR for evaluating hyperattenuating incidental adrenal masses. Radiology 243 (2007) 760-765
29. Korobkin M., Giordano T.J., Brodeur F.J., et al. Adrenal adenomas: relationship between histologic lipid and CT and MR findings. Radiology 200 (1996) 743-747
30. Honigschnabl S., Gallo S., Niederle B., et al. How accurate is MR imaging in characterisation of adrenal masses: update of a long-term study. European Journal of Radiology 41 (2002) 113-122
31. Al-Hawary M.M., Francis I.R., and Korobkin M. Non-invasive evaluation of the incidentally detected indeterminate adrenal mass. Best Practice & Research. Clinical Endocrinology & Metabolism 19 (2005) 277-292
32. Faria J.F., Goldman S.M., Szejnfeld J., et al. Adrenal masses: characterization with in vivo proton MR spectroscopy-initial experience. Radiology 245 (2007) 788-797
33. Gross M.D., Shapiro B., Francis I.R., et al. Scintigraphy of incidentally discovered bilateral adrenal masses. European Journal of Nuclear Medicine 22 (1995) 315-321
34. Han S.J., Kim T.S., Jeon S.W., et al. Analysis of adrenal masses by 18F-FDG positron emission tomography scanning. International Journal of Clinical Practice 61 (2007) 802-809
35. Caoili E.M., Korobkin M., Brown R.K., et al. Differentiating adrenal adenomas from nonadenomas using (18)F-FDG PET/CT: quantitative and qualitative evaluation. Academic Radiology 14 (2007) 468-475
36. Metser U., Miller E., Lerman H., et al. 18F-FDG PET/CT in the evaluation of adrenal masses. Journal of Nuclear Medicine 47 (2006) 32-37
37. Khan T.S., Sundin A., Juhlin C., et al. 11C-metomidate PET imaging of adrenocortical cancer. Eur J Nucl Med Mol Imaging 30 (2003) 403-410
38. Hennings J., Lindhe O., Bergstrom M., et al. [11C]metomidate positron emission tomography of adrenocortical tumors in correlation with histopathological findings. The Journal of Clinical Endocrinology and Metabolism 91 (2006) 1410-1414
39. Hahner S., Stuermer A., Kreissl M., et al. [123 I]Iodometomidate for molecular imaging of adrenocortical cytochrome P450 family 11B enzymes. The Journal of Clinical Endocrinology and Metabolism 93 (2008) 2358-2365
40. Mackie G.C., Shulkin B.L., Ribeiro R.C., et al. Use of [18F]fluorodeoxyglucose positron emission tomography in evaluating locally recurrent and metastatic adrenocortical carcinoma. The Journal of Clinical Endocrinology and Metabolism 91 (2006) 2665-2671
41. Leboulleux S., Dromain C., Bonniaud G., et al. Diagnostic and prognostic value of 18-fluorodeoxyglucose positron emission tomography in adrenocortical carcinoma: a prospective comparison with computed tomography. The Journal of Clinical Endocrinology and Metabolism 91 (2006) 920-925
42. Schteingart D.E., Doherty G.M., Gauger P.G., et al. Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr Relat Cancer 12 (2005) 667-680
43. Volante M., Buttigliero C., Greco E., et al. Pathological and molecular features of adrenocortical carcinoma: an update. Journal of Clinical Pathology 61 (2008) 787-793
44. Weiss L.M., Medeiros L.J., and Vickery Jr. A.L. Pathologic features of prognostic significance in adrenocortical carcinoma. American Journal of Surgical Pathology 13 (1989) 202-206
45. Hough A.J., Hollifield J.W., Page D.L., et al. Prognostic factors in adrenal cortical tumors. A mathematical analysis of clinical and morphologic data. American Journal of Clinical Pathology 72 (1979) 390-399
46. van Slooten H., Schaberg A., Smeenk D., et al. Morphologic characteristics of benign and malignant adrenocortical tumors. Cancer 55 (1985) 766-773
47. Goldblum J.R., Shannon R., Kaldjian E.P., et al. Immunohistochemical assessment of proliferative activity in adrenocortical neoplasms. Modern Pathology 6 (1993) 663-668
48. Vargas M.P., Vargas H.I., Kleiner D.E., et al. Adrenocortical neoplasms: role of prognostic markers MIB-1, P53, and RB. American Journal of Surgical Pathology 21 (1997) 556-562
49. Terzolo M., Boccuzzi A., Bovio S., et al. Immunohistochemical assessment of Ki-67 in the differential diagnosis of adrenocortical tumors. Urology 57 (2001) 176-182
50. Wachenfeld C., Beuschlein F., Zwermann O., et al. Discerning malignancy in adrenocortical tumors: are molecular markers useful?. European Journal of Endocrinology 145 (2001) 335-341
51. Morimoto R., Satoh F., Murakami O., et al. Immunohistochemistry of a proliferation marker Ki67/MIB1 in adrenocortical carcinomas: Ki67/MIB1 labeling index is a predictor for recurrence of adrenocortical carcinomas. Endocrine Journal 55 (2008) 49-55
52. Saeger W. Histopathological classification of adrenal tumours. European Journal of Clinical Investigation 30 (2000) 58-62
53. Saeger W., Fassnacht M., Chita R., et al. High diagnostic accuracy of adrenal core biopsy: results of the German and Austrian adrenal network multicenter trial in 220 consecutive patients. Human Pathology 34 (2003) 180-186
54. Sasano H., Suzuki T., and Moriya T. Recent advances in histopathology and immunohistochemistry of adrenocortical carcinoma. Endocrine Pathology 17 (2006) 345-354
55. Tissier F., Louvel A., Grabar S., et al. Cyclin E correlates with malignancy and adverse prognosis in adrenocortical tumors. European Journal of Endocrinology 150 (2004) 809-817
56. Libe R., and Bertherat J. Molecular genetics of adrenocortical tumours, from familial to sporadic diseases. European Journal of Endocrinology 153 (2005) 477-487
57. DeLellis R.A., Lloyd R.V., Heitz P.U., et al. World Health Organization classification of tumours. Pathology and Genetics of Tumours of Endocrine Organs (2004) p. 136
58. Macfarlane D.A. Cancer of the adrenal cortex: the natural history, prognosis and treatment in a study of fifty-five cases. Annals of the Royal College of Surgeons of England 23 (1958) 155-186
59. Sullivan M., Boileau M., and Hodges C.V. Adrenal cortical carcinoma. The Journal of Urology 120 (1978) 660-665
60. Fassnacht M, Johanssen S, Quinkler M, et al. Limited prognostic value of the 2004 UICC staging classification for adrenocortical carcinoma - proposal for a revised TNM classification. Cancer 2009 Jan 15;115(2): 243-250.
61. Hedican S.P., and Marshall F.F. Adrenocortical carcinoma with intracaval extension. The Journal of Urology 158 (1997) 2056-2061
62. Gonzalez R.J., Shapiro S., Sarlis N., et al. Laparoscopic resection of adrenal cortical carcinoma: a cautionary note. Surgery 138 (2005) 1078-1085 [discussion: 1085-6]
63. Kebebew E., Siperstein A.E., Clark O.H., et al. Results of laparoscopic adrenalectomy for suspected and unsuspected malignant adrenal neoplasms. Archives of Surgery 137 (2002) 948-951 [discussion: 952-3]
64. Schlamp A., Hallfeldt K., Mueller-Lisse U., et al. Recurrent adrenocortical carcinoma after laparoscopic resection. Nature Clinical Practice, Endocrinology & Metabolism 3 (2007) 191-195 quiz 1 p following 195
65. Pommier R.F., and Brennan M.F. An eleven-year experience with adrenocortical carcinoma. Surgery 112 (1992) 963-970 [discussion: 970-1]
66. Stojadinovic A., Ghossein R.A., Hoos A., et al. Adrenocortical carcinoma: clinical, morphologic, and molecular characterization. Journal of Clinical Oncology 20 (2002) 941-950
67. Terzolo M., Angeli A., Fassnacht M., et al. Adjuvant mitotane treatment in patients with adrenocortical carcinoma. The New England Journal of Medicine 356 (2007) 372-380
68. Fassnacht M., Hahner S., Polat B., et al. Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. The Journal of Clinical Endocrinology and Metabolism 91 (2006) 4501-4504
69. Khan T.S., Imam H., Juhlin C., et al. Streptozocin and o,p'DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use. Annals of Oncology 11 (2000) 1281-1287
70. Wood B.J., Abraham J., Hvizda J.L., et al. Radiofrequency ablation of adrenal tumors and adrenocortical carcinoma metastases. Cancer 97 (2003) 554-560
71. Rhim H., Dodd III G.D., Chintapalli K.N., et al. Radiofrequency thermal ablation of abdominal tumors: lessons learned from complications. Radiographics 24 (2004) 41-52
72. Brown D.B. Concepts, considerations, and concerns on the cutting edge of radiofrequency ablation. Journal of Vascular and Interventional Radiology 16 (2005) 597-613
73. Berruti A., Terzolo M., Sperone P., et al. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr Relat Cancer 12 (2005) 657-666
74. Kirschner L.S. Emerging treatment strategies for adrenocortical carcinoma: a new hope. The Journal of Clinical Endocrinology and Metabolism 91 (2006) 14-21
75. Quinkler M., Hahner S., Wortmann S., et al. Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine. The Journal of Clinical Endocrinology and Metabolism 93 (2008) 2057-2062
76. Samnotra V., Vassilopoulou-Sellin R., and Fojo A.T. A phase II trial of gefitinib monotherapy in patients with unresectable adrenocortical carcinoma (ACC). Proceedings of the Annual Meeting of the American Society of Clinical Oncology (2007) [abstract no 15527]
77. Chacon R., Tossen G., Loria F.S., et al. CASE 2. Response in a patient with metastatic adrenal cortical carcinoma with thalidomide. Journal of Clinical Oncology 23 (2005) 1579-1580
78. Giordano T.J., Thomas D.G., Kuick R., et al. Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. American Journal of Pathology 162 (2003) 521-531
79. de Fraipont F., El Atifi M., Cherradi N., et al. Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic Acid microarrays identifies several candidate genes as markers of malignancy. The Journal of Clinical Endocrinology and Metabolism 90 (2005) 1819-1829
80. Almeida MQ, Fragoso MC, Lotfi CF, et al. Expression of IGF-II and its receptor in pediatric and adult adrenocortical tumors. The Journal of Clinical Endocrinology and Metabolism 2008 Sep;93(9): 3524-3531.
81. Miller J.W., and Crapo L. The medical treatment of Cushing's syndrome. Endocrine Reviews 14 (1993) 443-458
82. Fassnacht M., Hahner S., Beuschlein F., et al. New mechanisms of adrenostatic compounds in a human adrenocortical cancer cell line. European Journal of Clinical Investigation 30 Suppl. 3 (2000) 76-82
83. Contreras P., Rojas A., Biagini L., et al. Regression of metastatic adrenal carcinoma during palliative ketoconazole treatment. Lancet 2 (1985) 151-152
84. Johanssen S & Allolio B. Mifepristone (RU 486) in Cushing's syndrome. European Journal of Endocrinology 2007; 157: 561-569; Castinetti F, Fassnacht M, Johanssen S, et al. Merits and pitfalls of mifepristone in Cushing's syndrome. 2009 Mar 16. [Epub ahead of print].
85. Schulte H.M., Benker G., Reinwein D., et al. Infusion of low dose etomidate: correction of hypercortisolemia in patients with Cushing's syndrome and dose-response relationship in normal subjects. The Journal of Clinical Endocrinology and Metabolism 70 (1990) 1426-1430
86. Bergenstal D., Lipsett M., Moy R., et al. Regression of adrenal cancer and suppression of adrenal function in men by o,p-DDD. Transactions of American Physicians 72 (1959) 341
87. Hahner S., and Fassnacht M. Mitotane for adrenocortical carcinoma treatment. Current Opinion in Investigational Drugs 6 (2005) 386-394
88. van Slooten H., Moolenaar A.J., van Seters A.P., et al. The treatment of adrenocortical carcinoma with o,p'-DDD: prognostic implications of serum level monitoring. European Journal of Cancer & Clinical Oncology 20 (1984) 47-53
89. Haak H.R., Hermans J., van de Velde C.J., et al. Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. British Journal of Cancer 69 (1994) 947-951
90. Baudin E., Pellegriti G., Bonnay M., et al. Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p'DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer 92 (2001) 1385-1392
91. Terzolo M., Pia A., Berruti A., et al. Low-dose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer. The Journal of Clinical Endocrinology and Metabolism 85 (2000) 2234-2238
92. Faggiano A., Leboulleux S., Young J., et al. Rapidly progressing high o,p'DDD doses shorten the time required to reach the therapeutic threshold with an acceptable tolerance: preliminary results. Clinical Endocrinology 64 (2006) 110-113
93. Nader N., Raverot G., Emptoz-Bonneton A., et al. Mitotane has an estrogenic effect on sex hormone-binding globulin and corticosteroid-binding globulin in humans. The Journal of Clinical Endocrinology and Metabolism 91 (2006) 2165-2170
94. Dickstein G., Shechner C., Arad E., et al. Is there a role for low doses of mitotane (o,p'-DDD) as adjuvant therapy in adrenocortical carcinoma?. The Journal of Clinical Endocrinology and Metabolism 83 (1998) 3100-3103
95. Venkatesh S., Hickey R.C., Sellin R.V., et al. Adrenal cortical carcinoma. Cancer 64 (1989) 765-769
96. Soreide J.A., Brabrand K., and Thoresen S.O. Adrenal cortical carcinoma in Norway, 1970-1984. World Journal of Surgery 16 (1992) 663-667 [discussion 668]
97. Bellantone R., Ferrante A., Boscherini M., et al. Role of reoperation in recurrence of adrenal cortical carcinoma: results from 188 cases collected in the Italian National Registry for Adrenal Cortical Carcinoma. Surgery 122 (1997) 1212-1218
98. Schulick R.D., and Brennan M.F. Adrenocortical carcinoma. World Journal of Urology 17 (1999) 26-34
99. Vassilopoulou-Sellin R., and Schultz P.N. Adrenocortical carcinoma. Clinical outcome at the end of the 20th century. Cancer 92 (2001) 1113-1121
100. Assie G., Antoni G., Tissier F., et al. Prognostic parameters of metastatic adrenocortical carcinoma. The Journal of Clinical Endocrinology and Metabolism 92 (2007) 148-154